Last reviewed · How we verify
Trastuzumab + Pertuzumab
Trastuzumab and pertuzumab are monoclonal antibodies that block HER2 signaling by binding to different epitopes on the HER2 receptor, preventing tumor cell growth in HER2-positive cancers.
Trastuzumab and pertuzumab are monoclonal antibodies that block HER2 signaling by binding to different epitopes on the HER2 receptor, preventing tumor cell growth in HER2-positive cancers. Used for HER2-positive metastatic breast cancer, HER2-positive early-stage breast cancer (neoadjuvant and adjuvant settings), HER2-positive gastric or gastroesophageal junction cancer.
At a glance
| Generic name | Trastuzumab + Pertuzumab |
|---|---|
| Also known as | Herceptin, Herceptin + Perjeta |
| Sponsor | Massachusetts General Hospital |
| Drug class | HER2-targeted monoclonal antibody combination |
| Target | HER2 (human epidermal growth factor receptor 2) |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | FDA-approved |
Mechanism of action
Trastuzumab binds to domain IV of HER2, blocking ligand-independent signaling and promoting antibody-dependent cellular cytotoxicity. Pertuzumab binds to domain II of HER2, preventing heterodimerization with other HER family receptors. Together, they provide dual HER2 blockade, enhancing therapeutic efficacy in HER2-overexpressing tumors.
Approved indications
- HER2-positive metastatic breast cancer
- HER2-positive early-stage breast cancer (neoadjuvant and adjuvant settings)
- HER2-positive gastric or gastroesophageal junction cancer
Common side effects
- Cardiotoxicity / left ventricular dysfunction
- Infusion reactions
- Diarrhea
- Nausea
- Fatigue
- Neutropenia
- Headache
Key clinical trials
- HER2 Directed Dendritic Cell Vaccine During Neoadjuvant Therapy of HER2+Breast Cancer (EARLY_PHASE1)
- Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR) (PHASE2)
- Trastuzumab Deruxtecan in First-Line HER2-Positive Metastatic Breast Cancer With Proactive Toxicity Management (PHASE2)
- A Phase I Study to Compare the Pharmacokinetic Characteristics, Safety, and Immunogenicity of HLX319 and EU-Phesgo®. (PHASE1)
- Testing the Addition of Herceptin Hylecta or Phesgo to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carcinoma or Carcinosarcoma (PHASE3)
- A Clinical Study of Neoadjuvant Treatment With TQB2102 for Injection for Human Epidermal Growth Factor Receptor 2 (HER2) Positive Breast Cancer (PHASE3)
- Testing Trastuzumab and Pertuzumab in Patients With Higher Than Normal Copies of the HER2 Gene Found in Their Tumors (MATCH - Subprotocol J) (PHASE2)
- Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial) (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Trastuzumab + Pertuzumab CI brief — competitive landscape report
- Trastuzumab + Pertuzumab updates RSS · CI watch RSS
- Massachusetts General Hospital portfolio CI